These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1133 related items for PubMed ID: 19479805

  • 1. Donor livers with steatosis are safe to use in hepatitis C virus-positive recipients.
    Burra P, Loreno M, Russo FP, Germani G, Galligioni A, Senzolo M, Cillo U, Zanus G, Fagiuoli S, Rugge M.
    Liver Transpl; 2009 Jun; 15(6):619-28. PubMed ID: 19479805
    [Abstract] [Full Text] [Related]

  • 2. Impact of donor graft steatosis on overall outcome and viral recurrence after liver transplantation for hepatitis C virus cirrhosis.
    Briceño J, Ciria R, Pleguezuelo M, de la Mata M, Muntané J, Naranjo A, Sánchez-Hidalgo J, Marchal T, Rufián S, López-Cillero P.
    Liver Transpl; 2009 Jan; 15(1):37-48. PubMed ID: 19109846
    [Abstract] [Full Text] [Related]

  • 3. Mild donor liver steatosis has no impact on hepatitis C virus fibrosis progression following liver transplantation.
    Botha JF, Thompson E, Gilroy R, Grant WJ, Mukherjee S, Lyden ER, Fox IJ, Sudan DL, Shaw BW, Langnas AN.
    Liver Int; 2007 Aug; 27(6):758-63. PubMed ID: 17617118
    [Abstract] [Full Text] [Related]

  • 4. Natural history of post-liver transplantation hepatitis C: A review of factors that may influence its course.
    Gallegos-Orozco JF, Yosephy A, Noble B, Aqel BA, Byrne TJ, Carey EJ, Douglas DD, Mulligan D, Moss A, de Petris G, Williams JW, Rakela J, Vargas HE.
    Liver Transpl; 2009 Dec; 15(12):1872-81. PubMed ID: 19938138
    [Abstract] [Full Text] [Related]

  • 5. Impact of the donor risk index on the outcome of hepatitis C virus-positive liver transplant recipients.
    Maluf DG, Edwards EB, Stravitz RT, Kauffman HM.
    Liver Transpl; 2009 Jun; 15(6):592-9. PubMed ID: 19479802
    [Abstract] [Full Text] [Related]

  • 6. Impact of donor age on survival and fibrosis progression in patients with hepatitis C undergoing liver transplantation using HCV+ allografts.
    Khapra AP, Agarwal K, Fiel MI, Kontorinis N, Hossain S, Emre S, Schiano TD.
    Liver Transpl; 2006 Oct; 12(10):1496-503. PubMed ID: 16964597
    [Abstract] [Full Text] [Related]

  • 7. Use of severely steatotic grafts in liver transplantation: a matched case-control study.
    McCormack L, Petrowsky H, Jochum W, Mullhaupt B, Weber M, Clavien PA.
    Ann Surg; 2007 Dec; 246(6):940-6; discussion 946-8. PubMed ID: 18043095
    [Abstract] [Full Text] [Related]

  • 8. Older donor livers show early severe histological activity, fibrosis, and graft failure after liver transplantation for hepatitis C.
    Rayhill SC, Wu YM, Katz DA, Voigt MD, Labrecque DR, Kirby PA, Mitros FA, Kalil RS, Miller RA, Stolpen AH, Schmidt WN.
    Transplantation; 2007 Aug 15; 84(3):331-9. PubMed ID: 17700157
    [Abstract] [Full Text] [Related]

  • 9. Long-term outcome of hepatitis C infection after liver transplantation.
    Gane EJ, Portmann BC, Naoumov NV, Smith HM, Underhill JA, Donaldson PT, Maertens G, Williams R.
    N Engl J Med; 1996 Mar 28; 334(13):815-20. PubMed ID: 8596547
    [Abstract] [Full Text] [Related]

  • 10. High incidence of allograft cirrhosis in hepatitis C virus genotype 1b infection following transplantation: relationship with rejection episodes.
    Prieto M, Berenguer M, Rayón JM, Córdoba J, Argüello L, Carrasco D, García-Herola A, Olaso V, De Juan M, Gobernado M, Mir J, Berenguer J.
    Hepatology; 1999 Jan 28; 29(1):250-6. PubMed ID: 9862874
    [Abstract] [Full Text] [Related]

  • 11. Donor age affects fibrosis progression and graft survival after liver transplantation for hepatitis C.
    Machicao VI, Bonatti H, Krishna M, Aqel BA, Lukens FJ, Nguyen JH, Rosser BG, Satyanarayana R, Grewal HP, Hewitt WR, Harnois DM, Crook JE, Steers JL, Dickson RC.
    Transplantation; 2004 Jan 15; 77(1):84-92. PubMed ID: 14724440
    [Abstract] [Full Text] [Related]

  • 12. Outcome of recurrent hepatitis C virus after liver transplantation in a randomized trial of tacrolimus monotherapy versus triple therapy.
    Manousou P, Samonakis D, Cholongitas E, Patch D, O'Beirne J, Dhillon AP, Rolles K, McCormick A, Hayes P, Burroughs AK.
    Liver Transpl; 2009 Dec 15; 15(12):1783-91. PubMed ID: 19938143
    [Abstract] [Full Text] [Related]

  • 13. Use of liver grafts from donation after cardiac death donors for recipients with hepatitis C virus.
    Taner CB, Bulatao IG, Keaveny AP, Willingham DL, Pungpapong S, Perry DK, Rosser BG, Harnois DM, Aranda-Michel J, Nguyen JH.
    Liver Transpl; 2011 Jun 15; 17(6):641-9. PubMed ID: 21618684
    [Abstract] [Full Text] [Related]

  • 14. Survival and hepatitis C virus recurrence after liver transplantation in HIV- and hepatitis C virus-coinfected patients: experience in a single center.
    Testillano M, Fernandez JR, Suarez MJ, Gastaca M, Bustamante J, Pijoan JI, Montejo M, Valdivieso A, Ruiz P, Gonzalez J, Ortiz de Urbina J.
    Transplant Proc; 2009 Apr 15; 41(3):1041-3. PubMed ID: 19376421
    [Abstract] [Full Text] [Related]

  • 15. Recipient age affects long-term outcome and hepatitis C recurrence in old donor livers following transplantation.
    Selzner M, Kashfi A, Selzner N, McCluskey S, Greig PD, Cattral MS, Levy GA, Lilly L, Renner EL, Therapondos G, Adcock LE, Grant DR, McGilvray ID.
    Liver Transpl; 2009 Oct 15; 15(10):1288-95. PubMed ID: 19790152
    [Abstract] [Full Text] [Related]

  • 16. Hepatitis C recurrence is not adversely affected by the use of donation after cardiac death liver allografts.
    Tao R, Ruppert K, Cruz RJ, Malik SM, Shaikh O, Ahmad J, DiMartini A, Humar A, Fontes PA, de Vera ME.
    Liver Transpl; 2010 Nov 15; 16(11):1288-95. PubMed ID: 21031544
    [Abstract] [Full Text] [Related]

  • 17. Clinical experience gained from the use of 120 steatotic donor livers for orthotopic liver transplantation.
    Verran D, Kusyk T, Painter D, Fisher J, Koorey D, Strasser S, Stewart G, McCaughan G.
    Liver Transpl; 2003 May 15; 9(5):500-5. PubMed ID: 12740794
    [Abstract] [Full Text] [Related]

  • 18. Liver transplantation for HCV cirrhosis: improved survival in recent years and increased severity of recurrent disease in female recipients: results of a long term retrospective study.
    Belli LS, Burroughs AK, Burra P, Alberti AB, Samonakis D, Cammà C, De Carlis L, Minola E, Quaglia A, Zavaglia C, Vangeli M, Patch D, Dhillon A, Cillo U, Guido M, Fagiuoli S, Giacomoni A, Slim OA, Airoldi A, Boninsegna S, Davidson BR, Rolles K, Pinzello G.
    Liver Transpl; 2007 May 15; 13(5):733-40. PubMed ID: 17370330
    [Abstract] [Full Text] [Related]

  • 19. Contribution of marginal donors to liver transplantation for hepatitis C virus infection.
    Briceño J, Ciria R, Pleguezuelo M, Naranjo A, Sánchez-Hidalgo J, Ruiz-Rabelo J, López-Cillero P, Luque A, de la Mata M, Rufián S.
    Transplant Proc; 2007 Sep 15; 39(7):2297-9. PubMed ID: 17889169
    [Abstract] [Full Text] [Related]

  • 20. Contribution of donor age to the recent decrease in patient survival among HCV-infected liver transplant recipients.
    Berenguer M, Prieto M, San Juan F, Rayón JM, Martinez F, Carrasco D, Moya A, Orbis F, Mir J, Berenguer J.
    Hepatology; 2002 Jul 15; 36(1):202-10. PubMed ID: 12085366
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 57.